References
O’Reilly EM. Refinement of adjuvant therapy for pancreatic cancer. JAMA. 2010;304:1124–5.
Bao PQ, Ramanathan RK, Krasinkas A, et al. Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol. 2011;18:1122–9.
de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature. 2010;467(7315):543–9.
Roukos DH. Cancer genome explosion and systems biology: Impact on surgical oncology? Ann Surg Oncol. 2011;18(1):12–15.
Katsios C, Roukos DH. Individual genomes and personalized medicine: Life diversity and complexity. Per Med. 2010;7(4):347–50.
Roukos DH. Bionetworks-based personalized medicine versus comparative effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn. 2010;10(3):247–50.
Roukos DH. Next generation, genome sequencing-based biomarkers: Concerns and challenges for medical practice. Biomark Med. 2010;4(4):583–6.
Roukos DH. Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices. 2011;8(2):123–6.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zoras, O., Batsis, C. Erlotinib and Pancreatic Adenocarcinoma: Uncertainty and Hope. Ann Surg Oncol 18 (Suppl 3), 246–247 (2011). https://doi.org/10.1245/s10434-011-1809-x
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-011-1809-x